Peripheral Blood Eosinophils, Fresh
Human peripheral blood eosinophils are isolated from whole peripheral blood in a multi-step process. First, whole peripheral blood is treated with HetaSep to deplete red blood cells. Granulocytes are further enriched via density gradient centrifugation and processed to remove remaining red blood cells. Finally, eosinophils are negatively selected by depleting cells expressing CD2, CD3, CD14, CD16, CD19, CD20, CD36, CD56, CD123, and CD235a from the enriched granulocyte population leaving purified, untouched peripheral blood eosinophils. Isolated cells are characterized by flow cytometry to ensure a highly pure and viable cell population.
Cells were obtained using Institutional Review Board (IRB) approved consent forms and protocols.
|Cell and Tissue Source||Peripheral Blood|
|Donor Attributes||HIV-, HepB-, HepC-|
|Purity||≥85% by Flow Cytometry|
|Viability||≥85% by Flow Cytometry|
|Contains||PBS with 5% FBS and 0.5% BSA|